CHROMATOGRAM-BASED PREDICTORS OF HbA1c REPORTINGFAILUREANDPOSITIVEBIASONBIO-RADHPLC IN SAMPLES WITH ABNORMAL HAEMOGLOBIN PEAKS
Main Article Content
Keywords
HbA1c; haemoglobin variants; Bio-Rad D-10; Variant; HPLC; Roche Cobas; methodcomparison; India.
Abstract
Background:Abnormal haemoglobin peaks are frequently observed on Bio-Rad cation-exchangeHPLC for glycated haemoglobin (HbA1c), particularly in regions with a high prevalence ofhaemoglobinopathies. These peaks may cause assay failure or clinically relevant bias, but routinedata comparing Bio-Rad HPLC with immunoassay methods under such conditions are limited.
Objectives:TodeterminethefrequencyofHbA1creportingfailureonBio-RadD-10/VariantHPLCin the presence of abnormal peaks, quantify bias versus a Roche Cobas immunoturbidimetric assay,and identify chromatographic predictors of failure and large method differences.
Methods:In this retrospective laboratory study, we analysed 156 unique EDTA blood samples inwhich Bio-Rad D-10 or Variant chromatograms displayed at least one abnormal haemoglobin peakand a paired HbA1c result was available from a Roche Cobas analyser. Abnormal-peak type, areaunder the curve (AUC, % of total haemoglobin), retention times of HbA1c and the abnormal peak,and the distance between peaks were recorded. Bio-Rad results were classified as failures whenHbA1cwasreportedas0%or>20%despiteanumericCobasresult.Insampleswithnumericresultson both methods, we calculated the difference (ΔHbA1c = Bio-Rad − Cobas), the absolutedifference (|ΔHbA1c|), correlation and Bland–Altman limits of agreement. Logistic regression wasused to identify predictors of Bio-Rad failure.
Results:Variant-window peaks were the most frequent abnormality (107/156; 68.6%). Based onCobasHbA1c,61patients(39.1%)werenormoglycaemic,37(23.7%)hadprediabetesand58(37.2%)haddiabetes.Bio-Radfailedin26/156chromatograms(16.7%),reportingHbA1cas0%in23and>20%in3cases.FailurewasmorefrequentontheVariantthanontheD-10(Variant14/34,41.2%vsD-1012/122,9.8%).In the130analyzablepairs,meanHbA1cwas7.20%by Bio-Radand6.62% byCobas,withameanbiasof0.58%andlimitsofagreementfrom-1.1to2.2%.Overall,28.5%ofpaired results differed by≥1.0 percentage point. Abnormal-peak AUC showed a modest positivecorrelation with |ΔHbA1c| (r=0.19), whereas greater peak-distance proportion was associated withsmallerdifferences(r=-0.21).Inmultivariableanalysis,each1%increaseinAUCincreasedtheoddsof Bio-Rad failure (odds ratio 1.12; 95% CI 1.08–1.17), whereas each 0.1-min increase in peakdistance reduced the odds (odds ratio 0.34; 95% CI 0.19–0.60).
Conclusions:Insampleswithabnormalhaemoglobinpeaks,Bio-RadHPLCfrequentlyyieldsnon-reportable or positively biased HbA1c values when compared with a Roche Cobasimmunoturbidimetric assay. Large variant-window or unknown peaks close to the HbA1c windoware the main determinants of failure and bias. Simple chromatogram-based rules using peak area andretention-time separation may help laboratories flag high-risk chromatograms and trigger reflextesting on an alternative HbA1c method.
References
assayinthediagnosisofdiabetes.DiabetesCare.2009;32(7):1327–1334.
2.LittleRR,RohlfingCL,SacksDB.StatusofhemoglobinA1cmeasurementandgoalsfor
improvement:fromchaostoorderforimprovingdiabetescare.ClinChem.2011;57(2):205–214.3.LittleRR,RobertsWL.AreviewofvarianthemoglobinsinterferingwithhemoglobinA1c
measurement. J Diabetes Sci Technol. 2009;3(3):446–451.
4.Bio-Rad Laboratories. D-10Hemoglobin Testing System: Instruction Manual. Bio-Rad; current
edition.
5.Bio-RadLaboratories.VariantIIHemoglobinTestingSystem:InstructionManual.Bio-Rad;
current edition.
6.NGSP. HbA1c assay interferences. Available at: https://ngsp.org/interf.asp (accessed December
2025).
7.NGSP. Factors that interfere with HbA1c test results. Available at: https://ngsp.org/factors.asp
(accessed December 2025).
8.GhoshK,GhoshK,ShettyS.Beta-thalassemiaandhemoglobinopathiesinIndia:laboratory
diagnosis,epidemiology andclinical management.IntJ LabHematol.2009;31(4):365–381.
9.ColahR,ItaliaK,GorakshakarA.BurdenofthalassemiainIndia:Theroadahead.IndianJ
MedRes.2015;142(5):507–509.
10.RohlfingCL,ConnollySM,EnglandJD,etal.EffectsofhemoglobinC,D,EandStraitson
measurements of hemoglobin A1c by fifteen methods. Clin Chim Acta. 2016;455:80–83.
11.SacksDB.HemoglobinA1cindiabetes:panaceaorpointless?Diabetes.2013;62(1):41–43.
12.Gillett MJ. International Expert Committee report on the role of the A1c assay in the diagnosis
ofdiabetes: a critique. ClinBiochem Rev.2009;30(4):171–176.

